- Open Access
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option
© Willems et al; licensee BioMed Central Ltd. 2010
Received: 4 May 2010
Accepted: 23 September 2010
Published: 23 September 2010
Myxoid liposarcoma is a relatively common malignant soft tissue tumor, characterized by a (12;16) translocation resulting in a FUS-DDIT3 fusion gene playing a pivotal role in its tumorigenesis. Treatment options in patients with inoperable or metastatic myxoid liposarcoma are relatively poor though being developed and new hope is growing.
Using kinome profiling and subsequent pathway analysis in two cell lines and four primary cultures of myxoid liposarcomas, all of which demonstrated a FUS-DDIT3 fusion gene including one new fusion type, we aimed at identifying new molecular targets for systemic treatment. Protein phosphorylation by activated kinases was verified by Western Blot and cell viability was measured before and after treatment of the myxoid liposarcoma cells with kinase inhibitors. We found kinases associated with the atypical nuclear factor-kappaB and Src pathways to be the most active in myxoid liposarcoma. Inhibition of Src by the small molecule tyrosine kinase inhibitor dasatinib showed only a mild effect on cell viability of myxoid liposarcoma cells. In contrast, inhibition of the nuclear factor-kappaB pathway, which is regulated by the FUS-DDIT3 fusion product, in myxoid liposarcoma cells using casein kinase 2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) showed a significant decrease in cell viability, decreased phosphorylation of nuclear factor-kappaB pathway proteins, and caspase 3 mediated apoptosis. Combination of dasatinib and TBB showed an enhanced effect.
Kinases associated with activation of the atypical nuclear factor-kappaB and the Src pathways are the most active in myxoid liposarcoma in vitro and inhibition of nuclear factor-kappaB pathway activation by inhibiting casein kinase 2 using TBB, of which the effect is enhanced by Src inhibition using dasatinib, offers new potential therapeutic strategies for myxoid liposarcoma patients with advanced disease.
Myxoid liposarcoma accounts for 40% of all liposarcomas and occurs most commonly in the extremities . In about 95% of cases, myxoid liposarcoma is cytogenetically characterized by t(12;16)(q13;p11), creating a chimerical FUS/DDIT3 gene which has been thought to play a pivotal role in its tumourigenesis [2–4]. The cornerstone of curative treatment for myxoid liposarcoma is surgery with an overall 10 years survival of 80%. Prognosis is mainly determined by the percentage of round cell component of the tumor. Myxoid liposarcoma with more than 5% round cell component are defined as high-grade and prone to metastasis. Treatment options for patients with inoperable or metastatic disease are relatively poor, though trials with new drugs reveal good perspectives for the future [6, 7]. Therefore, clinical trials to test and validate new treatment options for liposarcoma subtypes (such as myxoid liposarcoma) are necessary. Nowadays, (neo) adjuvant chemotherapy of liposarcoma patients is limited with only ifosfamide and anthracyclins showing 20-40% response rates in untreated patients. Trabectedin (Yondelis, ET 743) is a novel chemotherapeutic agent derived from the marine tunicate Ecteinascidia turbinate. By binding to the DNA minor groove, ET-743 forms covalent adducts with the N2-position of guanine through its carbinolamine moiety. As a result, the minor groove bends toward the major groove. The cytotoxic activity of ET-743 is largely based on its interaction with nucleoside excision repair machinery, as well as through the induction of double strand breaks[9–11]. Phase I and II studies showed promising results in myxoid liposarcoma patients with advanced disease though recent studies reported an increasing number of side effects[12, 13]. During the last years, tumor specific targeted therapy has shown to be effective in many cancers, including sarcomas. Especially kinase inhibitors are an emerging class of small molecule inhibitors that target unique kinase conformational forms and binding sites. Notable advantages are higher specificity and generally more manageable and reversible side effects . This necessitates the study of separate soft tissue tumour entities. In the present study, we explored the activated pathways in myxoid liposarcoma cells using kinome profiling to find new treatment possibilities. Kinases phosphorylate tyrosine, threonine or serine residues on proteins, thereby serving as a switch to (in) activate pathways involved in cell cycle, cell survival and differentiation. Moreover, kinases are promising targets for anti-cancer therapy as they do not require new protein synthesis, therefore act rapidly and are also promising in slow-cycling tumors [16, 17].
Data on activated pathways in myxoid liposarcoma are sparse[18, 19]. By using a kinase substrate specific protein array chip combining 1024 different kinase substrates, we identified kinases associated with Src and NF-kappaB pathways to be active in myxoid liposarcoma. NF-kappaB is an inducible cellular transcription factor that regulates a variety of cellular genes, including those involved in immune regulation, inflammation, cell survival and cell proliferation. Hereby, active NF-kappaB plays a pivotal role in tumorigenesis and increased expression of the phosphorylated NF-kappaB protein is found in many tumors[20, 21]. We showed that in myxoid liposarcoma cells, inhibition of kinases associated with the NF-kappaB pathway (by TBB) resulted in decreased viability and that this effect was enhanced by Src-inhibitor dasatinib. These results show that targeting NF-kappaB pathway might be a potential treatment option in myxoid liposarcoma patients with advanced disease.
Molecular and cytogenetic analysis
Clinicopathological and genetic data of myxoid liposarcoma samples
FUS/DDIT3 transcript size
FUS/DDIT3 transcript type
left thigh, subcutaneously
Identification of active kinases and pathways
Top 100 activated kinases and targeted drugs in myxoid liposarcoma cell lines and primary cultures.
Number of hits
Casein kinase 2, alpha 1
Lymphocyte-specific protein tyrosine kinase
FYN oncogene related to SRC, FGR, YES
Calcium/calmodulin-dependent protein kinase II beta
Protein kinase, cAMP-dependent, catalytic, alpha
Mitogen-activated protein kinase 1 [
V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
dasatinib, sunitinib ao
Casein kinase 1, alpha 1
Calcium and integrin binding family
Glycogen synthase kinase 3
V-yes-1 Yamaguchi sarcoma viral related oncogene homolog
Bruton agammaglobulinemia tyrosine kinase
Protein kinase C
V-akt murine thymoma viral oncogene homolog 1
Pyruvate kinase, muscle
Calcium/calmodulin-dependent protein kinase I
CHK1 checkpoint homolog
CHK2 checkpoint homolog
Polo-like kinase 3
Abelson murine leukemia viral (v-abl) oncogene homolog
lispro, aspart, glargine
Epidermal growth factor receptor
cetuximab, canertinib ao
V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
Ribosomal protein S6
Mitogen-activated protein kinase kinase 3
G protein-coupled receptor kinase 1
Janus kinase 1
Mitogen-activated protein kinase-activated protein kinase 2
Anaplastic lymphoma receptor tyrosine kinase
Ataxia telangiectasia mutated
Protein kinase N1
Platelet-derived growth factor receptor, beta polypeptide
dasatinib, sunitib ao
Cyclin-dependent kinase 2
Cell cycle related kinase
Cell division cycle 2, G1 to S and G2 to M
Top lists of activated kinases and pathways in different conditions
top five activated kinases
top activated signalling pathway
normal medium condition (including all kinases in the analysis)
normal medium condition (leaving out cell cycle related kinases in the analysis)
starved medium condition
G1/S transition of the cell cycle
oxidative stress response
Verification of kinome profiling
In vitro targeting of kinases associated with Src and NF-kappaB pathways by dasatinib and TBB
Dasatinib inhibits phosphorylation of Src but does not cause apoptosis
TBB inhibits NF-kappaB p65-phosphorylation resulting in caspase-3 mediated apoptosis
To investigate the effect of TBB on kinases associated with NF-kappaB signalling, L1357 was treated with increasing doses for 6 hours. Whereas levels of total NF-kappaB p65 did not decrease upon treatment, a decrease in phosphorylated p65 (p-p65) was found (figure 4). At a dose of 20 μM TBB p-p65 staining slightly started to fade and obviously decreased at 200 μM TBB. Casein Kinase 2 levels of TBB treated samples were lower than the DMSO control, but remained unchanged compared to samples treated with various concentrations TBB or dasatinib, suggesting that TBB does not alter the overall expression of casein Kinase 2, which is in accordance with the literature. TBB treatment had no effect on the levels of total Src and phosphorylated Src. Strikingly, the effect of TBB was increased by pretreatment with dasatinib (figure 4), which was also visible in the viability assay (figure 3D). Moreover, there was a gradual increase in caspase-3 levels upon treatment with TBB, suggesting caspase-3 mediated apoptosis.
Treatment options for myxoid liposarcoma patients with advanced disease are poor. Recently, the chemotherapeutic drug Trabectedin showed promising results in phase I and II trials in advanced disease though adverse effects have also been reported[13, 25]. Small molecule targeting, especially with kinase inhibitors, has shown to be effective and more specific in many tumors with less severe side effects than conventional chemotherapeutic agents. To identify new potential treatment options for myxoid liposarcoma patients with advanced disease, we explored the kinome of myxoid liposarcoma cells in vitro and performed subsequent pathway analysis.
We previously established the reliability of kinome profiling using Pepchip in untreated versus imatinib treated GIST882 cell line which correctly identified the pathways known to be involved in GIST. Moreover, we previously demonstrated the reliability of our analysis which is based on averaging results of a number of samples to get an impression of the most activated kinases in a series of tumors. By additionally performing the Pepchip experiments in the myxoid liposarcomas cell lines after serum starvation as well as by excluding cell cycle related kinases from the analysis we determined that the detected kinases in the present analysis are indeed tumor specific and not related to the high proliferation rate of the myxoid liposarcoma cell lines. Moreover, by comparing with previously analyzed series of colorectal cancer and chondrosarcoma, as well as by comparing with mesenchymal stem cells we could confirm that the list of kinases was specific for myxoid liposarcomas.
We showed that kinases associated with NF-kappaB pathway were highly active in myxoid liposarcoma. In the atypical (IKK independent) NF-kappaB pathway, phosphorylation of inhibitors of NF-kappaB (IkB), and subsequent activation of NF-kappaB (p65) is controlled by casein kinase 2 and tyrosine kinase-dependent pathways (figure 5)[36, 37]. We did not measure NF-kappaB pathway activation by analysis of downstream products or electrophoretic mobility shift assays. Göransson et al. has recently s hown that NF-kappaB is a major factor controlling IL8 transcription in FUS-DDIT3 expressing cells. This could be explained by direct binding of FUS/DDIT3 to the C/EBP-NF-kappaB composite site of the immediate promoter region of IL8. Moreover, FUS/DDIT3-GFP expressing cell lines showed upregulation of the NF-kappaB controlled genes LCN2 and MMP1 whereas DDIT3 had little effect. These findings were also quantitatively confirmed by RT-PCR. Active (phosphorylated) p65 was present in cell lysates of myxoid liposarcoma cell cultures and cell lines. We did not explicitly show that the phosphorylated p65 protein was located in the nucleus/nuclear fraction. Phosphorylation of p65 could be counteracted by TBB, an inhibitor of the casein kinase 2 and resulted in decreased cell viability as shown in figure 3 and 4. This suggests that NF-kappaB signaling is active in myxoid liposarcoma and that its activation is, at least in part, regulated via the atypical pathway. This is an important finding which suggests that NF-kappaB pathway inhibition might be beneficial in myxoid liposarcoma patients with advanced disease.
The exact driving force behind NF-kappaB activation in myxoid liposarcoma is unclear. Gene expression studies revealed that p50 was significantly upregulated in FUS/DDIT3 transfected fibroblastic cell lines. This suggests that NF-kappaB (p50) transcription in myxoid liposarcoma might be regulated by the FUS/DDIT3 fusion gene. After translocation to the nucleus, transcriptional activation of NF-kappaB requires multiple co-activating proteins. The C-terminus of FUS co-activates p65 and plays a pivotal role in NF-kappaB mediated transcription though this C-terminus is lost in the FUS/DDIT3 fusion protein. Recent studies showed that the FUS/DDIT3 fusion protein facilitates NF-kappaB binding to its target genes, probably in an indirect manner[19, 39–41]. The FUS-DDIT3 fusion protein deregulates NF-kappaB controlled genes by interaction with nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor zeta (NFKBIZ). This synergistic role between a fusion protein and activation of NF-kappaB signaling might also be important in other translocation based sarcomas and has already been shown in Bcr-Abl mediated leukemias.
In all myxoid liposarcoma samples we showed overexpression of casein kinase 2, which has been shown in many other neoplasms. We showed inhibition of casein kinase 2 and subsequent decreased levels of active p65 to be associated with decreased viability and increase in caspase 3 protein expression in myxoid liposarcoma cells. Caspase 3 is released by cleavage of its inactive precursor procaspase 3, and mediates apoptosis[44, 45]. Decreased cell viability with increased levels of the effector caspase 3 therefore suggests caspase 3 mediated apoptosis. Recently, phase I trials have been started to test the effect of casein kinase 2 inhibitors in vivo which seems to be promising.
In addition to kinases associated with NF-kappaB, Fyn, Lck and Yes were most active as indicated by specific sequences on the chip. They are members of the Src family of kinases. Src plays an important role in embryonic development, cell growth and cell survival and activating mutations in Src have been reported in colorectal carcinoma[47, 48]. Src signaling can lead to downstream activation of ERK/MAPK and PI3K/AKT signaling. Activation of both pathways in myxoid liposarcoma is associated with more aggressive behavior. The Src pathway can be inhibited by the small molecule tyrosine kinase inhibitor dasatinib limiting cell growth in various cancers in vitro, thereby having promising therapeutic potential[16, 50, 51]. Immunoblotting confirmed the expression of Src and phosphorylation of Src at Y419 in myxoid liposarcoma cell cultures and cell lines. Dasatinib treatment showed a reduction in phosphorylated (active) Src and a decrease in cell viability. However, this latter effect was only very mild with maximum decrease in viability of only 40% maximally, and no IC50 levels could be calculated. This might be explained by Src pathway activation occurring upstream, close to its receptor (figure 5) and that the effect of the inhibition of Src phosphorylation might be (partly) circumvented by crosstalk activation downstream. Our data suggest that the active Src pathway is not crucial for myxoid liposarcoma survival and that monotherapy with dasatinib is no suitable option for treatment, although the additional effect of dasatinib in vivo through inhibition of angiogenesis is not encountered here.
Combinations of different drugs (including dasatinib) have been shown to act synergistically in many tumors and combination drug therapy is commonly used in cancer treatment. Recently, a synergistic effect of dasatinib when combined with other drugs (i.e. oxaliplatin) has been described in colorectal carcinoma. Since we showed NF-kappaB and Src to be the two most active pathways we studied the effect of combination of dasatinib and TBB and we found a enhanced effect on cell viability of myxoid liposarcoma cells in vitro. To be more specific: L1357 cells show 80% viability at maximum dasatinib dose (5000 nM), whereas viability was only 5% at lower concentration of dasatinib (500 nM) at IC50 for TBB (figure 3). However, it was not possible to calculate if this enhancement was also a true synergistic effect as IC50 values for dasatinib could not be calculated (figure 3). IC50 values for TBB (but not for dasatinib) could be calculated for most primary cultures and cell lines, but not for L1187 and L1434. Though cell line 1765-92 responded well to TBB treatment, no enhancement could be observed upon addition of dasatinib, which might be related to a relative resistance of 1765-92 cells to dasatinib as also visible from figure 3A. Future experiments, for instance studying the changes at the kinome level upon dasatinib treatment may reveal (1) why dasatinib is not effective as a monotherapy but is effective in combination with TBB, and (2) what might be the exact underlying mechanism why 1765-92 myxoid liposarcoma cells showed resistance for dasatinib treatment and thereby the absence of enhancement in combination treatment as was observed for the other cell line and primary cultures.
In conclusion our results indicate that the NF-kappaB and Src pathway include the most active kinases in myxoid liposarcoma, and inhibition of casein kinase 2 and thereby interference with kinases associated with the NF-kappaB pathway decreases cell viability in vitro, the effect of which can be enhanced by inhibiting src- signalling using dasatinib.
Dasatinib (Sprycel, BMS- 354825) was obtained from Bristol-Myers Squibb (New York, USA) and TBB from Calbiochem (San Diego, CA). Both drugs were dissolved in Dimethylsulfoxide (DMSO).
Cell cultures and cell lines
The two myxoid liposarcoma cell lines 402-91 and 1765-92, and gastro-intestinal stroma cell tumor cell line (GIST882) were kindly provided by Prof. Dr. P. Aman (Lundberg Laboratory for Cancer Research, Department of Pathology, Göteborg University, Goteburg, Sweden) and Prof. Dr. J. Fletcher (Brigham and Women's Hospital, Boston, USA) respectively[53, 54]. Jurkat and HeLa cell lines (American Type Culture Collection, Rockville, MD) were used as positive controls for Western blotting. Myxoid liposarcoma cell lines, primary cultures of four myxoid liposarcomas (L1187, L1357, L1434 and L2187) and two cell cultures of normal bone marrow derived mesenchymal stem cells (L2361 and L2370) were cultured in RPMI 1640 (Gibco, Invitrogen Life-Technologies, Scotland, UK), supplemented with 10% heat-inactivated fetal calf serum (Gibco). Cells were grown in a humidified incubator at 37°C with 5% CO2. In addition, two samples (402-19 and L1357) were analyzed after also culturing in starved RPMI 1640, containing 0,5% fetal calf serum.
RT-PCR and karyotyping
Diagnosis of the primary tumors from which the cultures were obtained was performed on histology. Primary tumors were analyzed for their tumor specific translocation with double-fusion fluorescence in situ hybridization (FISH) and cell lines were karyotyped with Combined Binary Ratio Labeling (COBRA) as previously described [55–57]. In primary cultures, tumor cells were genotyped for the presence of the fusion gene by RT-PCR. Total RNA was isolated using TRIzol (Invitrogen, Breda, The Netherlands). Complementary DNA was synthesized from 1 μg of total RNA using oligo dT primers and Superscript II MMLV reverse transcriptase (Life Technologies, Carlsbad, CA). Reverse-transcription polymerase chain reaction (RT-PCR), sample purification and DNA sequence analysis were performed as described previously . The following primers were used: FUS-forward, CAG AGC TCC CAA TCG TCT TAC GG and DDIT3-reverse, GAG AAA GGC AAT GAC TCA GCT GCC.
Kinome array analysis
Kinase substrate peptide arrays (Pepchip Kinomics, Pepscan Presto, Lelystad, the Netherlands) containing 1024 different kinase substrates spotted in triplicate together with 16 negative, and 16 positive controls were used and successfully used in prior studies [16, 59]. The distribution of the target sequences in terms of kinase recognition is described in detail on the website http://www.pepscanpresto.com/index.php?id=30. Cells were harvested during their exponential growth phase and lysated as previously described. Concentration of the protein lysates was measured using the DC Protein Assay (Biorad, Hercules, CA, USA). Analysis was performed as described earlier, including the two serum-starved samples. Autoradiographic signals were sensed by phosphoimage screen and scanned by Typhoon 9400 phosphoimager (GE Healthcare, Piscataway, NJ). At least 1 × 106 hits were collected.
The scanned images were analyzed and quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). For further data mining R-packages Affyio and Limma were used http://www.bioconductor.org. Quality of the triplicates and distribution of the data was assessed and quartile normalization (Affyio) was performed as previously described. Median intensities of the triplicates were calculated and the top 100 spots were imported for core analysis in Ingenuity Pathway Analysis (IPA, Ingenuity Systems, http://www.ingenuity.com). IPA is a literature based program that calculates the probability of involvement of identifiers, in this case combinations of kinases, in 74 different pathways. Data of the myxoid liposarcoma cell lines and cultures were averaged to find the common denominators that are active in all cultures. To ensure that artificially induced kinase activity due to cell culturing interfered with tumor specific kinase activity, the same analysis was run excluding cell cycle related kinases as well as after starvation. Specificity of activated kinases and activated pathways in myxoid liposarcoma was verified by comparison the same analysis of four colorectal carcinoma cell lines and thirteen chondrosarcoma cell lines and cultures using Limma.
Western blotting was performed as previously described. Rabbit polyclonal antibody to phosphorylated Src (Y419) was obtained from R&D Systems (1/2000; Minneapolis, MN USA). Monoclonal antibody to total Src and alpha-tubulin were obtained from Upstate Biotechnology (clone GD11, 1/2000, Lake Placid, NY, USA) and Sigma Aldrich (St. Louise, MO, USA), respectively. Rabbit polyclonal antibodies against casein kinase 2alpha; NF-kappaB p65, phospho- NF-kappaB p65 (S468) and caspase 3 were obtained from Cell Signaling Technology (Beverly, MA). HeLa cell lines, untreated and treated with TNFalpha (20 ng/ml) were used as a positive control for casein kinase 2alpha and NF-kappaB p65/phospho- NF-kappaB p65, respectively, according to the manufacturer's protocol.
In vitro viability assays
Measurement of metabolic activity by a WST-1 colorimetric assay (Roche Diagnostics GmbH, Penzberg, Germany) was used as a read-out system for cell viability in response to kinase inhibitors. Dasatinib was used to inhibit Src-pathway; TBB was used to inhibit casein kinase 2, which is an important kinase in atypical NF-kappaB signalling. After harvesting, 2000 cells/well of every cell line and primary culture were seeded into 96-well flat-bottom plates. After 24 hours, increasing concentrations of the drugs (50, 100, 200, 500, 1000 and 5000 nM for dasatinib and 10, 20, 50, 100, 200 and 500 μM for TBB respectively) were added or 0,1% DMSO as vehicle control, each condition in quadruplicate. Ten percent serum supplementation was used for all experiments. After 3 days of treatment, absorbance was measured on a Victor Multilabel Counter 1420-042 (Perkin Elmer, Groningen, The Netherlands) at 450 nm, and was corrected for background and averaged. GIST882 and Jurkat cell lines were used as positive controls for dasatinib and TBB experiments, respectivelyy. In combination experiments, 2000 cells were plated overnight followed by treatment with dasatinib which was added 30 minutes after TBB administration. In these experiments, increasing concentrations of dasatinib at IC50 concentrations of TBB were used.
The authors are grateful to Prof. Dr. Pierre Aman (Lundberg Laboratory for Cancer Research (LLCR), Department of Pathology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden) for providing myxoid liposarcoma cell lines 402-91 and 1765-92, Prof. Dr. J. Fletcher (Brigham and Women's Hospital, Boston, USA) for providing the GIST882 cell line, Prof. Dr. Bob van de Water and Ine Tijdens (both from the Division of Toxicology, Leiden Amsterdam Center for Drug Research (LACDR), Leiden University, Leiden, The Netherlands) for expert technical support with the read out of the Pepchips. We are grateful to Jolieke van Oosterwijk for help with the WST experiments and Dr. Christianne Reijnders for culturing the mesenchymal stem cells. Brandt Meylis is acknowledged for expert technical assistance. This work was supported by a grant from the Netherlands Organisation for Scientific Research [920-03-403].
- Antonescu C, Ladanyi M: Myxoid liposarcoma. World Health Organization classification of tumours. pathology and genetics. Tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2004, 40-43. Lyon: IARC press, 2002,Google Scholar
- Willems SM, Wiweger M, Graadt van Roggen JF, Hogendoorn PCW: Running GAGs: myxoid matrix in tumor pathology revisited: What's in it for the pathologist?. Virchows Arch. 2010, 456: 181-192. 10.1007/s00428-009-0822-yPubMed CentralView ArticlePubMedGoogle Scholar
- Turc-Carel C, Limon J, Dal Cin P, Rao U, Karakousis C, Sandberg AA: Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet. 1986, 23: 291-299. 10.1016/0165-4608(86)90011-7View ArticlePubMedGoogle Scholar
- Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P: Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 1996, 12: 489-494.PubMedGoogle Scholar
- Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR, Ladanyi M: Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001, 7: 3977-3987.PubMedGoogle Scholar
- Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le CA, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007, 8: 595-602. 10.1016/S1470-2045(07)70175-4View ArticlePubMedGoogle Scholar
- Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009, 20: 1439-1444. 10.1093/annonc/mdp004View ArticlePubMedGoogle Scholar
- Dalal KM, Antonescu CR, Singer S: Diagnosis and management of lipomatous tumors. J Surg Oncol. 2008, 97: 298-313. 10.1002/jso.20975View ArticlePubMedGoogle Scholar
- Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA. 2007, 104: 13062-13067. 10.1073/pnas.0609877104PubMed CentralView ArticlePubMedGoogle Scholar
- Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996, 35: 13303-13309. 10.1021/bi960306bView ArticlePubMedGoogle Scholar
- Zewail-Foote M, Hurley LH: Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999, 42: 2493-2497. 10.1021/jm990241lView ArticlePubMedGoogle Scholar
- Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S: Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol. 2009, 27: e198-e200. 10.1200/JCO.2008.21.6473View ArticlePubMedGoogle Scholar
- Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009, 27: 4188-4196. 10.1200/JCO.2008.21.0088View ArticlePubMedGoogle Scholar
- Tuveson DA, Fletcher JA: Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol. 2001, 13: 249-255. 10.1097/00001622-200107000-00007View ArticlePubMedGoogle Scholar
- Widakowich C, de CG, de Azambuja E, Dinh P, Awada A: Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007, 12: 1443-1455. 10.1634/theoncologist.12-12-1443View ArticlePubMedGoogle Scholar
- Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AHM, van Wezel T, Hogendoorn PCW, Bovee JVMG: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009, 69: 6216-6222. 10.1158/0008-5472.CAN-08-4801View ArticlePubMedGoogle Scholar
- Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P: Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer. 2005, 115: 556-560. 10.1002/ijc.20893View ArticlePubMedGoogle Scholar
- Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010, 42: 715-721. 10.1038/ng.619PubMed CentralView ArticlePubMedGoogle Scholar
- Goransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, Mantovani R, Aman P: The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene. 2009, 28: 270-278. 10.1038/onc.2008.378View ArticlePubMedGoogle Scholar
- Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870View ArticlePubMedGoogle Scholar
- Richmond A: Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002, 2: 664-674. 10.1038/nri887PubMed CentralView ArticlePubMedGoogle Scholar
- Panagopoulos I, Mertens F, Isaksson M, Mandahl N: A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun. 2000, 279: 838-845. 10.1006/bbrc.2000.4026View ArticlePubMedGoogle Scholar
- Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA: Selectivity of 4, 5, 6, 7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001, 496: 44-48. 10.1016/S0014-5793(01)02404-8View ArticlePubMedGoogle Scholar
- Trembley JH, Wang G, Unger G, Slaton J, Ahmed K: Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009, 66: 1858-1867. 10.1007/s00018-009-9154-yPubMed CentralView ArticlePubMedGoogle Scholar
- Grant SK: Therapeutic protein kinase inhibitors. Cell Mol Life Sci. 2009, 66: 1163-1177. 10.1007/s00018-008-8539-7View ArticlePubMedGoogle Scholar
- Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M, Abollo-Jimenez F, Pintado B, Sanchez-Garcia I: FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One. 2008, 3: e2569- 10.1371/journal.pone.0002569PubMed CentralView ArticlePubMedGoogle Scholar
- Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008, 77: 289-312. 10.1146/annurev.biochem.77.061307.091829View ArticlePubMedGoogle Scholar
- Willems SM, van RA, van ZR, Deelder AM, McDonnell LA, Hogendoorn PC: Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol. 2010, ,Google Scholar
- Crozat A, Aman P, Mandahl P, Ron D: Fusion of CHOP a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993, 363: 640-644. 10.1038/363640a0View ArticlePubMedGoogle Scholar
- Kuroda M, Ishida T, Takanashi M, Satoh M, Machinami R, Watanabe T: Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol. 1997, 151: 735-744.PubMed CentralPubMedGoogle Scholar
- Riggi N, Cironi L, Provero P, Suva ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I: Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006, 66: 7016-7023. 10.1158/0008-5472.CAN-05-3979View ArticlePubMedGoogle Scholar
- Engstrom K, Willen H, Kabjorn-Gustafsson C, Andersson C, Olsson M, Goransson M, Jarnum S, Olofsson A, Warnhammar E, Aman P: The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol. 2006, 168: 1642-1653. 10.2353/ajpath.2006.050872PubMed CentralView ArticlePubMedGoogle Scholar
- Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999, 96: 3951-3956. 10.1073/pnas.96.7.3951PubMed CentralView ArticlePubMedGoogle Scholar
- Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A: A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer. 2003, 89: 1409-1412. 10.1038/sj.bjc.6601306PubMed CentralView ArticlePubMedGoogle Scholar
- Huang HY, Antonescu CR: Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct Pathol. 2003, 27: 217-226. 10.1080/01913120309917View ArticlePubMedGoogle Scholar
- Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007, 8: 49-62. 10.1038/nrm2083View ArticlePubMedGoogle Scholar
- Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE: Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002, 62: 6770-6778.PubMedGoogle Scholar
- Schwarzbach MH, Koesters R, Germann A, Mechtersheimer G, Geisbill J, Winkler S, Niedergethmann M, Ridder R, Buechler MW, von Knebel DM, Willeke F: Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. Oncogene. 2004, 23: 6798-6805. 10.1038/sj.onc.1207840View ArticlePubMedGoogle Scholar
- Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M, Okamoto T: Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem. 2001, 276: 13395-13401. 10.1074/jbc.M011176200View ArticlePubMedGoogle Scholar
- Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA. 1997, 94: 2927-2932. 10.1073/pnas.94.7.2927PubMed CentralView ArticlePubMedGoogle Scholar
- Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ: Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science. 1997, 275: 523-527. 10.1126/science.275.5299.523View ArticlePubMedGoogle Scholar
- Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS: A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998, 12: 968-981. 10.1101/gad.12.7.968PubMed CentralView ArticlePubMedGoogle Scholar
- Duncan JS, Litchfield DW: Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2008, 1784: 33-47.View ArticlePubMedGoogle Scholar
- Riedl SJ, Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004, 5: 897-907. 10.1038/nrm1496View ArticlePubMedGoogle Scholar
- Hengartner MO: The biochemistry of apoptosis. Nature. 2000, 407: 770-776. 10.1038/35037710View ArticlePubMedGoogle Scholar
- Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, Diaz A, Castillo D, Ramos T, Gomez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, Lopez-Saura P: Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer. 2009, 9: 146- 10.1186/1471-2407-9-146PubMed CentralView ArticlePubMedGoogle Scholar
- Rudd CE, Trevillyan JM, Dasgupta JD, Wong LL, Schlossman SF: The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc Natl Acad Sci USA. 1988, 85: 5190-5194. 10.1073/pnas.85.14.5190PubMed CentralView ArticlePubMedGoogle Scholar
- Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ: Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 1999, 21: 187-190. 10.1038/5971View ArticlePubMedGoogle Scholar
- Cheng H, Dodge J, Mehl E, Liu S, Poulin N, van de RM, Nielsen TO: Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol. 2009, 40: 1244-1251. 10.1016/j.humpath.2009.01.011View ArticlePubMedGoogle Scholar
- Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 2009, 69: 3842-3849. 10.1158/0008-5472.CAN-08-2246PubMed CentralView ArticlePubMedGoogle Scholar
- Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR: Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009, 27: 77-83. 10.1038/nbt.1513PubMed CentralView ArticlePubMedGoogle Scholar
- Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10View ArticlePubMedGoogle Scholar
- Thelin-Jarnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P: Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer. 1999, 83: 30-33. 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4View ArticlePubMedGoogle Scholar
- Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A, Mitelman F: Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 1992, 5: 278-285. 10.1002/gcc.2870050403View ArticlePubMedGoogle Scholar
- Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PCW, Sciot R: Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006, 19: 407-416. 10.1038/modpathol.3800550View ArticlePubMedGoogle Scholar
- Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-de Bruijn IH, Knijnenburg J, Cleton-Jansen AM, Sciot R, Fletcher CDM, Deelder AM, Szuhai K, Hensbergen PJ, Hogendoorn PCW: Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med. 2009, 13: 1291-1301. 10.1111/j.1582-4934.2009.00747.xPubMed CentralView ArticlePubMedGoogle Scholar
- Szuhai K, Tanke HJ: COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nat Protoc. 2006, 1: 264-275. 10.1038/nprot.2006.41View ArticlePubMedGoogle Scholar
- Willems SM, Schrage YM, Baelde JJ, Briaire-de Bruijn I, Mohseny A, Sciot R, Bovee JVMG, Hogendoorn PCW: Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology. 2008, 52: 465-474. 10.1111/j.1365-2559.2008.02967.xView ArticlePubMedGoogle Scholar
- Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ: Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68: 1213-1220. 10.1158/0008-5472.CAN-07-5172View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.